# Baiyiyuan Biotech

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/baiyiyuan-biotech

- Industry: Healthcare
- Headquarters: Shanghai, China
- Website: www.biomedmat.com
- Latest round: Series B (Apr 12, 2018)
- Investors on record: 1

## About

Established in 2011 and based in Shanghai, Beijing, Baiyiyuan Biotech operates as a biomedical materials developer that provides medical plaster and medical film for tissue repair. The founder, Baiyi Han, graduated with a PhD from Kobe University. The company has applied more than 40 patents, and has been recognized as a National High-Tech Enterprise. It has set up 2 GMP industrialisation bases in Shanghai and Nanting. In April 2018, Baiyiyuan Biotech raised series B funding from new investor Yinying Capital.  In May 2025, the firm raised strategic investment from new investor China Medical System Holdings Limited. Baiyiyuan Biotech has established a core patented technology platform based on Bio SIS-ECM. The company's main product is a biopatch made from the submucosa of porcine small intestine. The products can be used for all types of tissue repair, filling, guided tissue regeneration. The company also provides users with products such as medical wound masks as well as medical cold packs. The company generates revenue by offering biopatch made from the submucosa of porcine small intestine and medical wound masks as well as medical cold packs. The company will use the funding for new product research and development, market development and production line upgrades.

## Funding rounds

- Series B, Apr 12, 2018 — Yinying Capital

## Investors

- Yinying Capital (https://capitalatlas.ai/funds/yinying-capital) — Series B